Newsfeeds - Spark Newswire

1 minute read

Events
News

Cytokinetics Outlines Go-To-Market Strategy For Omecamtiv Mecarbil And Provides Updates On Cardiovascular Pipeline At Today’s Analyst & Investor Day

Today, 12:47 PM

Cytokinetics, Incorporated (NASDAQ:CYTK) plans to outline the company’s go-to-market strategy for omecamtiv mecarbil in the United States, and present updates on the company’s advancing cardiovascular

CYTK

1 minute read

Jefferies Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $75

By Benzinga Newsdesk

Today, 12:47 PM

Jefferies analyst Akash Tewari initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and announces Price Target of $75.

CYTK

5 minute read

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal

By Shanthi Rexaline

Today, 12:47 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)

ABEO

6 minute read

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout

By Shanthi Rexaline

Today, 12:47 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)

ADTX

5 minute read

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO

By Shanthi Rexaline

Today, 12:47 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)

ADMA

1 minute read

Media

Cramer Weighs In On Cytokinetics, LegalZoom And Matterport

By Craig Jones

Today, 12:47 PM

On CNBC's "Mad Money Lightning Round," Jim Cramer said Cytokinetics, Inc. (NASDAQ: CYTK) is a very good spec. Big pharma needs these companies, he added.

CYTK